FBRX is expected to report earnings to fall 23.15% to -20 cents per share on November 11
Q3'24
Est.
$-0.21
Q2'24
Missed
by $0.11
Q1'24
Est.
$-0.16
Q4'23
Beat
by $0.28
Q3'23
Beat
by $0.31
The last earnings report on August 14 showed earnings per share of -27 cents, missing the estimate of -15 cents. With 6.17K shares outstanding, the current market capitalization sits at 11.13M.
a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer